# Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy

> **NCT01353079** · PHASE3 · COMPLETED · sponsor: **Greer Laboratories** · enrollment: 429 (actual)

## Conditions studied

- Allergy

## Interventions

- **BIOLOGICAL:** Short Ragweed Pollen Allergenic Extract
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01353079
- **Lead sponsor:** Greer Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2011-11
- **Final completion:** 2012-04
- **Target enrollment:** 429 (ACTUAL)
- **Last updated:** 2015-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01353079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01353079, "Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01353079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*